The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMTPH.L Share News (MTPH)

  • There is currently no data for MTPH

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Positive Headline Reading For Latest Midatech MTD201 Study

Wed, 08th Jan 2020 09:51

(Alliance News) - Midatech Pharma PLC on Wednesday posted positive headline results from study 102 of its MTD201 drug.

Shares in the Cardiff-headquartered biotechnology firm were up 9.1% at 3.00 pence in London in morning trading.

MTD201 is a long-acting form of the drug octreotide and is being developed by Midatech to treat acromegaly and neuroendocrine tumours. Acromelagy is hormone disorder which can cause bones in the hands, feet, and face to get bigger. Neuroendocrine tumours affect the cells responsible for releasing hormones.

The study met its primary endpoints, confirming a similar overall extended octreotide bioavailability and pharmacokinetic profile in both subcutaneous and intramuscular injections of the drug.

This is good news for MTD201 because subcutaneous injection, where the injection is given under the skin, is simpler and less painful than injection into the muscles.

Further, the trial also showed MTD201 delivered sustained concentrations of the drug in the plasma at the level needed to be effective at an injection interval of between six and eight weeks using either injection method.

This would cut the annual number of injections per patient from the current level of 12 injections per year to just 6.

The study was conducted on 28 healthy subjects, who were given either a subcutaneous or intramuscular injection of MTD201 in early October and observed for a period of 63 days.

Midatech Chief Executive Craig Cook said: "We are very pleased with the positive results of study 102. It confirmed both the subcutaneous dosing route for MTD201, as well as the potential for extended dosing intervals. These are key advantages for patients, physicians and payors, being the first therapy to offer this, and also gives Midatech a competitive advantage versus others as we move the product through to potential approval."

By Anna Farley; annafarley@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News
11 Apr 2016 12:20

Midatech Pharma Announces Launch Of Zuplenz In US

Read more
6 Jan 2016 10:18

WINNERS & LOSERS SUMMARY: ARM Hit By iPhone Production Cut Report

Read more
6 Jan 2016 07:57

Midatech Pharma 2015 Revenue To Come In Ahead Of Expectations

Read more
4 Jan 2016 14:18

Midatech particle technology to be used in vaccines

(ShareCast News) - Midatech Pharma's proprietary technology received a boost on Monday, with the news it had signed a licensing agreement with a private British biotechnology company. The AIM-listed pharmaceutical company - focused on products in oncology and other therapeutic areas - reported it ha

Read more
4 Jan 2016 07:35

Midatech Pharma Signs Licensing Deal With Emergex Vaccines

Read more
18 Dec 2015 09:53

Midatech Pharma Agrees To Buy Zuplenz From Galena Biopharma

Read more
18 Dec 2015 09:39

BROKER RATINGS SUMMARY: UBS Initiates Restaurant Group At Buy

Read more
14 Dec 2015 08:28

Midatech Pharma Appoints Centurion Pharma For Q-Octreotide In Turkey

Read more
4 Dec 2015 09:33

BROKER RATINGS SUMMARY: Barclays Downgrades Whitbread To Equal Weight

Read more
19 Nov 2015 10:00

Midatech Pharma Files Supplemental Disclosure In Relation To DARA Buy

Read more
15 Sep 2015 08:42

BROKER RATINGS SUMMARY: UBS Initiates Legal & General With Sell

Read more
14 Sep 2015 08:08

Midatech Pharma Loss Widens On Acquisition Costs, Investment

Read more
13 Aug 2015 07:00

Midatech Signs Deal With Eye Disesases Company Ophthotech

Read more
23 Jul 2015 08:04

Midatech Pharma Begins Phase IIa Study For MSL-001

Read more
23 Jun 2015 14:57

DIRECTOR DEALINGS: Midatech Pharma Finance Director Buys 500 Shares

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.